BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. The Lancet Gastroenterology & Hepatology 2017;2:200-10. [DOI: 10.1016/s2468-1253(16)30182-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 12.4] [Reference Citation Analysis]
Number Citing Articles
1 Walker A, Boyce A, Geller G, Thio CL, Kahn JP. Direct-Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype. Clin Infect Dis 2018;67:983-4. [PMID: 29617735 DOI: 10.1093/cid/ciy239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Butt ZA, Wong S, Rossi C, Binka M, Wong J, Yu A, Darvishian M, Alvarez M, Chapinal N, Mckee G, Gilbert M, Tyndall MW, Krajden M, Janjua NZ. Concurrent Hepatitis C and B Virus and Human Immunodeficiency Virus Infections Are Associated With Higher Mortality Risk Illustrating the Impact of Syndemics on Health Outcomes. Open Forum Infect Dis 2020;7:ofaa347. [PMID: 32964065 DOI: 10.1093/ofid/ofaa347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Janjua NZ, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team. Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. Hepatol Commun 2019;3:478-92. [PMID: 30976739 DOI: 10.1002/hep4.1307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
4 Yi S, Mun P, Chhoun P, Chann N, Tuot S, Mburu G. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduct J 2019;16:29. [PMID: 31036011 DOI: 10.1186/s12954-019-0299-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G. Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduct J 2021;18:102. [PMID: 34641896 DOI: 10.1186/s12954-021-00552-x] [Reference Citation Analysis]
6 Wang Y, Zhao Z, Wang M, Hannah MN, Hu Q, Rui J, Liu X, Zhu Y, Xu J, Yang M, Cui JA, Su Y, Zhao B, Chen T. The transmissibility of hepatitis C virus: a modelling study in Xiamen City, China. Epidemiol Infect 2020;148:e291. [PMID: 33234178 DOI: 10.1017/S0950268820002885] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Wong J, Tyndall MW, Janjua NZ; The BC-HTC Team. Hepatitis C cross-genotype immunity and implications for vaccine development. Sci Rep 2017;7:12326. [PMID: 28951612 DOI: 10.1038/s41598-017-10190-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
8 Panagiotoglou D, Krebs E, Min JE, Olding M, Ahamad K, Ti L, Montaner JSG, Nosyk B. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV? Int J Drug Policy 2017;47:169-76. [PMID: 28578865 DOI: 10.1016/j.drugpo.2017.05.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kapadia SN, Marks KM. Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers. Clin Ther 2018;40:1234-45. [PMID: 29983266 DOI: 10.1016/j.clinthera.2018.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
10 Liu Y, Zou X, Chen W, Gong C, Ling L. Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. Int J Environ Res Public Health 2019;16:E4436. [PMID: 31726750 DOI: 10.3390/ijerph16224436] [Reference Citation Analysis]
11 Falade-Nwulia O, Sulkowski MS, Merkow A, Latkin C, Mehta SH. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25:220-227. [PMID: 29316030 DOI: 10.1111/jvh.12859] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
12 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
13 Hackman J, Falade-Nwulia O, Patel EU, Mehta SH, Kirk GD, Astemborski J, Ray SC, Thomas DL, Laeyendecker O. Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore. Infect Genet Evol 2020;77:104078. [PMID: 31669367 DOI: 10.1016/j.meegid.2019.104078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
14 Ma H, Villalobos CF, St-Jean M, Eyawo O, Lavergne MR, Ti L, Hull MW, Yip B, Wu L, Hogg RS, Barrios R, Shoveller JA, Montaner JSG, Lima VD. The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study. BMC Health Serv Res 2018;18:319. [PMID: 29720155 DOI: 10.1186/s12913-018-3119-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sundberg I, Lannergård A, Ramklint M, Cunningham JL. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry 2018;18:157. [PMID: 29843679 DOI: 10.1186/s12888-018-1735-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
16 Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review. Curr HIV/AIDS Rep 2020;17:354-72. [PMID: 32314325 DOI: 10.1007/s11904-020-00498-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Zhou J, Zhang J, Zhou J, Yi H, Lin Z, Liu Y, Zhu M, Wang H, Zhang W, Xu H, Jiang H, Xiang Z, Qu Z, Yang Y, Lu L, Guo S, Fu H, Adcock IM, Wei Y, Yao X. Clinical characteristics of re-positive COVID-19 patients in Huangshi, China: A retrospective cohort study. PLoS One 2020;15:e0241896. [PMID: 33147282 DOI: 10.1371/journal.pone.0241896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Breskin A, Westreich D, Hurt CB, Cole SR, Hudgens MG, Seaberg EC, Thio CL, Tien PC, Adimora AA. The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus. Clin Infect Dis 2019;69:1613-20. [PMID: 30615096 DOI: 10.1093/cid/ciz008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ströh LJ, Krey T. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development. Int J Mol Sci 2020;21:E6781. [PMID: 32947858 DOI: 10.3390/ijms21186781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Hack B, Timalsina U, Tefera E, Wilkerson B, Paku E, Fernandez S, Fishbein D. Oral Prescription Opioids as a High-Risk Indicator for Hepatitis C Infection: Another Step Toward HCV Elimination. J Prim Care Community Health 2021;12:21501327211034379. [PMID: 34467805 DOI: 10.1177/21501327211034379] [Reference Citation Analysis]
21 Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis 2021;8:ofab511. [PMID: 34926713 DOI: 10.1093/ofid/ofab511] [Reference Citation Analysis]
22 Childs E, Assoumou SA, Biello KB, Biancarelli DL, Drainoni ML, Edeza A, Salhaney P, Mimiaga MJ, Bazzi AR. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. Harm Reduct J 2019;16:14. [PMID: 30744628 DOI: 10.1186/s12954-019-0286-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Williams LD, Mackesy-Amiti ME, Latkin C, Boodram B. Drug use-related stigma, safer injection norms, and hepatitis C infection among a network-based sample of young people who inject drugs. Drug Alcohol Depend 2021;221:108626. [PMID: 33689967 DOI: 10.1016/j.drugalcdep.2021.108626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Caven M, Baiano CX, Robinson EM, Stephens B, Macpherson I, Dillon JF. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. J Viral Hepat 2021;28:1744-50. [PMID: 34525228 DOI: 10.1111/jvh.13614] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Campo DS, Khudyakov Y. Intelligent Network DisRuption Analysis (INDRA): A targeted strategy for efficient interruption of hepatitis C transmissions. Infect Genet Evol 2018;63:204-15. [PMID: 29860098 DOI: 10.1016/j.meegid.2018.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
27 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Butt ZA, Shrestha N, Wong S, Kuo M, Gesink D, Gilbert M, Wong J, Yu A, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook VJ, Roth D, Consolacion T, Murti M, Hottes TS, Ogilvie G, Balshaw R, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort. A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One 2017;12:e0183609. [PMID: 28829824 DOI: 10.1371/journal.pone.0183609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
29 Gowda C, Lo Re V 3rd. Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. Curr Hepatol Rep 2018;17:111-20. [PMID: 30294518 DOI: 10.1007/s11901-018-0394-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis. PLoS One 2018;13:e0201268. [PMID: 30044871 DOI: 10.1371/journal.pone.0201268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
31 Butt ZA, Shrestha N, Gesink D, Murti M, Buxton JA, Gilbert M, Balshaw RF, Wong S, Kuo M, Wong J, Yu A, Alvarez M, Samji H, Roth D, Consolacion T, Hull MW, Ogilvie G, Tyndall MW, Krajden M, Janjua NZ. Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals. Clin Epidemiol 2018;10:1127-45. [PMID: 30214316 DOI: 10.2147/CLEP.S173449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 McKee G, Butt ZA, Wong S, Salway T, Gilbert M, Wong J, Alvarez M, Chapinal N, Darvishian M, Tyndall MW, Krajden M, Janjua NZ. Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study. EClinicalMedicine 2018;4-5:99-108. [PMID: 31193601 DOI: 10.1016/j.eclinm.2018.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
33 Hill LA, Martin NK, Torriani FJ, Jain S, Qin H, Mathews WC, Cachay ER. Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV. Open Forum Infect Dis 2021;8:ofaa643. [PMID: 33553480 DOI: 10.1093/ofid/ofaa643] [Reference Citation Analysis]
34 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]